Bcr-Abl

DB07107 is a potent inhibitor of the T315I mutant Bcr-Abl tyrosine kinase, demonstrating resistance against this specific mutation associated with chronic myeloid leukemia. Additionally, DB07107 effectively inhibits Akt1 with an IC50 value of 360 nM, highlighting its dual-targeting capability. This compound is suitable for research applications related to cancer signaling pathways and the development of targeted therapies for resistant forms of leukemia.

Nilotinib hydrochloride is a potent Bcr-Abl tyrosine kinase inhibitor that exhibits significant antineoplastic activity. It is primarily utilized in research related to chronic myelogenous leukemia (CML), providing valuable insights into the molecular mechanisms of this disease and potential therapeutic strategies. Its oral bioavailability makes it a convenient choice for in vitro and in vivo studies focused on targeting the Bcr-Abl fusion protein.

GZD856 formic is a selective inhibitor of PDGFRα/β, displaying IC50 values of 68.6 nM and 136.6 nM, respectively, along with potent inhibition of Bcr-Abl, including the T315I mutant with IC50s of 19.9 nM and 15.4 nM. This compound exhibits notable antitumor activity, making it a valuable tool for cancer research. Additionally, GZD856 formic serves as a click chemistry reagent due to its alkyne group, enabling copper-catalyzed azide-alkyne cycloaddition (CuAAc) with azide-containing molecules, facilitating bioconjugation studies and compound labeling.

S116836 is a potent BCR-ABL tyrosine kinase inhibitor that effectively targets both wild-type and T315I BCR-ABL variants. It induces apoptosis and arrests the cell cycle in the G0/G1 phase, promoting increased reactive oxygen species (ROS) and reduced glutathione (GSH) levels in BaF3/WT and BaF3/T315I cells. Additionally, S116836 inhibits SRC, LYN, HCK, LCK, BLK, as well as receptor tyrosine kinases including FLT3, TIE2, KIT, and PDGFR-β, demonstrating significant antitumor activity. This compound also features an alkyne group, making it suitable for click chemistry applications, particularly the copper-catalyzed azide-alkyne cycloaddition (CuAAc).

Asciminib (ABL001) is a potent and selective allosteric Bcr-Abl inhibitor; inhibits Ba/F3 cells grown with an IC50 of 0.25 nM.

SNIPER(ABL)-020 is a PROTAC compound designed to selectively degrade the BCR-ABL fusion protein through targeted ubiquitin-proteasome pathway engagement. By conjugating Dasatinib, an ABL inhibitor, with Bestatin, an IAP ligand, SNIPER(ABL)-020 effectively promotes the protein's ubiquitination and subsequent degradation. This reagent is valuable for research focused on chronic myeloid leukemia and BCR-ABL related signaling pathways, offering insights into targeted protein degradation mechanisms in cancer therapeutics.